ACME Laboratories has been growing earnings at an average annual rate of 8.6%, while the Pharmaceuticals industry saw earnings growing at 3.7% annually. Revenues have been growing at an average rate of 13.7% per year. ACME Laboratories's return on equity is 9.5%, and it has net margins of 6.7%.
Key information
8.61%
Earnings growth rate
8.61%
EPS growth rate
Pharmaceuticals Industry Growth
11.00%
Revenue growth rate
13.66%
Return on equity
9.52%
Net Margin
6.66%
Last Earnings Update
31 Mar 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ACME Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DSE:ACMELAB Revenue, expenses and earnings (BDT Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
40,045
2,666
9,930
0
31 Dec 25
38,857
2,563
9,496
0
30 Sep 25
37,482
2,512
8,970
0
30 Jun 25
35,937
2,429
8,534
0
31 Mar 25
34,746
2,403
8,353
0
31 Dec 24
33,499
2,391
8,068
0
30 Sep 24
32,352
2,350
7,779
0
30 Jun 24
31,932
2,456
7,539
0
31 Mar 24
30,811
2,420
7,187
0
31 Dec 23
29,394
2,374
6,929
0
30 Sep 23
28,280
2,342
6,704
0
30 Jun 23
26,948
2,304
6,424
0
31 Mar 23
25,869
2,202
6,005
0
31 Dec 22
25,334
2,169
5,748
0
30 Sep 22
24,506
2,144
5,574
0
30 Jun 22
23,858
2,111
5,381
0
31 Mar 22
23,203
1,985
5,117
0
31 Dec 21
22,386
1,872
4,855
0
30 Sep 21
21,735
1,742
4,670
0
30 Jun 21
20,770
1,569
4,457
0
31 Mar 21
20,341
1,503
4,146
0
31 Dec 20
19,875
1,467
3,950
0
30 Sep 20
19,516
1,465
3,771
0
30 Jun 20
19,004
1,450
3,551
0
31 Mar 20
18,161
1,421
3,612
0
31 Dec 19
17,465
1,435
3,362
0
30 Sep 19
16,859
1,452
3,120
0
30 Jun 19
16,309
1,440
3,018
0
31 Mar 19
15,955
1,377
3,014
0
31 Dec 18
15,542
1,400
2,935
0
30 Sep 18
15,155
1,394
2,923
0
30 Jun 18
14,814
1,427
2,843
0
31 Mar 18
14,708
1,449
2,789
0
31 Dec 17
14,335
1,443
2,675
0
30 Sep 17
13,943
1,440
2,562
0
30 Jun 17
13,576
1,398
2,522
0
31 Mar 17
13,358
1,523
2,509
0
31 Dec 16
13,270
1,389
2,454
0
30 Sep 16
12,967
1,250
2,385
0
30 Jun 16
12,645
1,101
2,305
0
31 Mar 16
12,396
990
2,072
0
Quality Earnings: ACMELAB has high quality earnings.
Growing Profit Margin: ACMELAB's current net profit margins (6.7%) are lower than last year (6.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACMELAB's earnings have grown by 8.6% per year over the past 5 years.
Accelerating Growth: ACMELAB's earnings growth over the past year (10.9%) exceeds its 5-year average (8.6% per year).
Earnings vs Industry: ACMELAB earnings growth over the past year (10.9%) exceeded the Pharmaceuticals industry 10.5%.
Return on Equity
High ROE: ACMELAB's Return on Equity (9.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/30 16:47
End of Day Share Price
2026/06/30 00:00
Earnings
2026/03/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The ACME Laboratories Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.